Barbara Rellahan
Barbara Rellahan, rellahan@amgen.com, is director, product quality at Amgen.
Articles
Saroj Ramdas;Renata Varga;Martin Gastens;Twinkle R. Christian;Bharat Jagannathan;Barbara Rellahan;Jillian Brady
March 16th 2021Many biologic drug manufacturers encounter similiar challenges; precompetitive collaboration can help resolve these issues. Representatives of the IQ Consortium’s Biologics CMC Leadership Group describe efforts to address the safe handling of biologic drugs in closed-system transfer devices in healthcare settings and the need for phase-appropriate specifications.
Latest Updated Articles
Published: October 11th 2024 | Updated: October 18th 2024
Buy, Sell, Hold: Cell and Gene Therapy - Part 1
Published: September 10th 2024 | Updated: September 18th 2024
CPHI Milan Announces 2024 CPHI Pharma Award Finalists
Published: February 23rd 2024 | Updated: December 22nd 2024
Europa Perspectives: Helping to Navigate the Regulatory System
Published: December 13th 2024 | Updated: December 22nd 2024
FDA Creates CDER Center for Real-World Evidence Innovation
Published: December 5th 2024 | Updated: December 22nd 2024
Leveraging Advancements in Bioanalytical Testing
Published: December 7th 2024 | Updated: December 22nd 2024
Exploring Opportunities for LNP Delivery in mRNA
